380 related articles for article (PubMed ID: 25964296)
1. Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.
Barth MJ; Mavis C; Czuczman MS; Hernandez-Ilizaliturri FJ
Clin Cancer Res; 2015 Oct; 21(19):4391-7. PubMed ID: 25964296
[TBL] [Abstract][Full Text] [Related]
2. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.
Barth MJ; Hernandez-Ilizaliturri FJ; Mavis C; Tsai PC; Gibbs JF; Deeb G; Czuczman MS
Br J Haematol; 2012 Feb; 156(4):490-8. PubMed ID: 22150234
[TBL] [Abstract][Full Text] [Related]
3. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines.
Takei K; Yamazaki T; Sawada U; Ishizuka H; Aizawa S
Leuk Res; 2006 May; 30(5):625-31. PubMed ID: 16289746
[TBL] [Abstract][Full Text] [Related]
4. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.
Ge X; Wu L; Hu W; Fernandes S; Wang C; Li X; Brown JR; Qin X
Clin Cancer Res; 2011 Nov; 17(21):6702-11. PubMed ID: 21918174
[TBL] [Abstract][Full Text] [Related]
5. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
6. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.
Golay J; Lazzari M; Facchinetti V; Bernasconi S; Borleri G; Barbui T; Rambaldi A; Introna M
Blood; 2001 Dec; 98(12):3383-9. PubMed ID: 11719378
[TBL] [Abstract][Full Text] [Related]
7. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
Alinari L; Yu B; Christian BA; Yan F; Shin J; Lapalombella R; Hertlein E; Lustberg ME; Quinion C; Zhang X; Lozanski G; Muthusamy N; Prætorius-Ibba M; O'Connor OA; Goldenberg DM; Byrd JC; Blum KA; Baiocchi RA
Blood; 2011 Apr; 117(17):4530-41. PubMed ID: 21228331
[TBL] [Abstract][Full Text] [Related]
8. Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab.
Sebejova L; Borsky M; Jaskova Z; Potesil D; Navrkalova V; Malcikova J; Sramek M; Doubek M; Loja T; Pospisilova S; Mayer J; Trbusek M
Exp Hematol; 2014 Oct; 42(10):867-74.e1. PubMed ID: 24970561
[TBL] [Abstract][Full Text] [Related]
9. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.
Herter S; Herting F; Mundigl O; Waldhauer I; Weinzierl T; Fauti T; Muth G; Ziegler-Landesberger D; Van Puijenbroek E; Lang S; Duong MN; Reslan L; Gerdes CA; Friess T; Baer U; Burtscher H; Weidner M; Dumontet C; Umana P; Niederfellner G; Bacac M; Klein C
Mol Cancer Ther; 2013 Oct; 12(10):2031-42. PubMed ID: 23873847
[TBL] [Abstract][Full Text] [Related]
10. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
[TBL] [Abstract][Full Text] [Related]
11. Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.
Shi W; Han X; Yao J; Yang J; Shi Y
Leuk Res; 2012 Jun; 36(6):749-55. PubMed ID: 22475365
[TBL] [Abstract][Full Text] [Related]
12. Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement.
Okroj M; Eriksson I; Österborg A; Blom AM
Med Oncol; 2013 Dec; 30(4):759. PubMed ID: 24198205
[TBL] [Abstract][Full Text] [Related]
13. Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma.
Montraveta A; Xargay-Torrent S; López-Guerra M; Rosich L; Pérez-Galán P; Salaverria I; Beà S; Kalko SG; de Frias M; Campàs C; Roué G; Colomer D
Oncotarget; 2014 Feb; 5(3):726-39. PubMed ID: 24519895
[TBL] [Abstract][Full Text] [Related]
14. Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity.
Natsume A; Shimizu-Yokoyama Y; Satoh M; Shitara K; Niwa R
Cancer Sci; 2009 Dec; 100(12):2411-8. PubMed ID: 19758394
[TBL] [Abstract][Full Text] [Related]
15. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
[TBL] [Abstract][Full Text] [Related]
16. Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma.
Jiang VC; Liu Y; Jordan A; Leeming A; McIntosh J; Huang S; Zhang R; Cai Q; Chen Z; Li Y; Che Y; Nie L; Karlsson I; Mårtensson L; Kovacek M; Teige I; Frendéus B; Wang M
J Hematol Oncol; 2022 Apr; 15(1):42. PubMed ID: 35410313
[TBL] [Abstract][Full Text] [Related]
17. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
Cruz RI; Hernandez-Ilizaliturri FJ; Olejniczak S; Deeb G; Knight J; Wallace P; Thurberg BL; Kennedy W; Czuczman MS
Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019
[TBL] [Abstract][Full Text] [Related]
18. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
Golay J; Zaffaroni L; Vaccari T; Lazzari M; Borleri GM; Bernasconi S; Tedesco F; Rambaldi A; Introna M
Blood; 2000 Jun; 95(12):3900-8. PubMed ID: 10845926
[TBL] [Abstract][Full Text] [Related]
19. Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.
Rufener GA; Press OW; Olsen P; Lee SY; Jensen MC; Gopal AK; Pender B; Budde LE; Rossow JK; Green DJ; Maloney DG; Riddell SR; Till BG
Cancer Immunol Res; 2016 Jun; 4(6):509-19. PubMed ID: 27197068
[TBL] [Abstract][Full Text] [Related]
20. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
Front Immunol; 2020; 11():609941. PubMed ID: 33505398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]